share_log

Carnegie Capital Asset Management LLC Trims Stake in CVS Health Co. (NYSE:CVS)

Carnegie Capital Asset Management LLC Trims Stake in CVS Health Co. (NYSE:CVS)

Carnegie Capital Asset Management LLC Trims持有CVS Health Co.(纽约证券交易所代码:CVS)的股份
Defense World ·  2022/09/24 11:11

Carnegie Capital Asset Management LLC lowered its position in CVS Health Co. (NYSE:CVS – Get Rating) by 88.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,716 shares of the pharmacy operator's stock after selling 36,167 shares during the quarter. Carnegie Capital Asset Management LLC's holdings in CVS Health were worth $394,000 at the end of the most recent reporting period.

卡内基资本资产管理有限责任公司(Carnegie Capital Asset Management LLC)在最近一次向美国证券交易委员会(Securities And Exchange Commission)披露的信息中称,该公司第二季度将其在CVS Health Co.(NYSE:CVS-GET Rating)的持仓下调了88.5%。该公司在本季度出售了36,167股后,持有这家药房运营商的4,716股股票。在最近一个报告期结束时,卡内基资本资产管理有限责任公司在CVS Health持有的股份价值394,000美元。

Other hedge funds and other institutional investors have also made changes to their positions in the company. Macroview Investment Management LLC increased its position in shares of CVS Health by 128.3% during the first quarter. Macroview Investment Management LLC now owns 242 shares of the pharmacy operator's stock worth $25,000 after acquiring an additional 136 shares during the period. Claremont Financial Group Inc. bought a new position in CVS Health in the fourth quarter worth approximately $26,000. Stuart Chaussee & Associates Inc. grew its stake in CVS Health by 123.0% in the first quarter. Stuart Chaussee & Associates Inc. now owns 310 shares of the pharmacy operator's stock worth $31,000 after purchasing an additional 171 shares in the last quarter. Rise Advisors LLC bought a new position in CVS Health in the fourth quarter worth approximately $41,000. Finally, Carl Stuart Investment Advisor Inc. bought a new position in CVS Health in the first quarter worth approximately $41,000. Hedge funds and other institutional investors own 77.64% of the company's stock.

其他对冲基金和其他机构投资者也改变了他们在该公司的头寸。宏景投资管理有限公司在第一季度将其在CVS Health股票的持仓增加了128.3%。宏景投资管理有限责任公司现在拥有242股这家药房运营商的股票,价值2.5万美元,在此期间又购买了136股。克莱蒙特金融集团公司在第四季度购买了CVS Health的一个新头寸,价值约2.6万美元。今年第一季度,Stuart Chaussee&Associates Inc.在CVS Health的持股增加了123.0%。Stuart Chaussee&Associates Inc.现在持有这家药房运营商310股股票,价值3.1万美元,该公司在上个季度又购买了171股。Rise Advisors LLC在第四季度购买了CVS Health的一个新头寸,价值约41,000美元。最后,卡尔·斯图尔特投资顾问公司在第一季度购买了CVS Health的一个新头寸,价值约41,000美元。对冲基金和其他机构投资者持有该公司77.64%的股票。

Get
到达
CVS Health
CVS运行状况
alerts:
警报:

CVS Health Stock Performance

CVS Health股票表现

Shares of CVS stock opened at $98.35 on Friday. The firm has a market capitalization of $129.12 billion, a price-to-earnings ratio of 15.99, a price-to-earnings-growth ratio of 1.52 and a beta of 0.73. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.91 and a quick ratio of 0.65. The business has a fifty day moving average of $100.20 and a 200 day moving average of $99.25. CVS Health Co. has a 1 year low of $81.78 and a 1 year high of $111.25.

CVS股票上周五开盘报98.35美元。该公司市值为1,291.2亿美元,市盈率为15.99倍,市盈率为1.52倍,贝塔系数为0.73。该公司的债务权益比为0.67,流动比率为0.91,速动比率为0.65。该业务的50日移动均线切入位为100.20美元,200日移动均线切入位为99.25美元。CVS Health Co.的一年低点为81.78美元,一年高位为111.25美元。

CVS Health (NYSE:CVS – Get Rating) last released its quarterly earnings data on Wednesday, August 3rd. The pharmacy operator reported $2.40 earnings per share for the quarter, beating analysts' consensus estimates of $2.16 by $0.24. The business had revenue of $80.64 billion during the quarter, compared to analyst estimates of $76.38 billion. CVS Health had a return on equity of 15.19% and a net margin of 2.65%. The company's revenue was up 11.0% on a year-over-year basis. During the same quarter last year, the business posted $2.42 EPS. As a group, research analysts expect that CVS Health Co. will post 8.53 earnings per share for the current year.
CVS Health(NYSE:CVS-GET Rating)最近一次发布季度收益数据是在8月3日星期三。这家药房运营商公布本季度每股收益为2.40美元,比分析师普遍预期的2.16美元高出0.24美元。该业务本季度营收为806.4亿美元,而分析师预期为763.8亿美元。CVS Health的股本回报率为15.19%,净利润率为2.65%。该公司的收入同比增长了11.0%。去年同一季度,该业务公布的每股收益为2.42美元。研究分析师预计,作为一个整体,CVS Health Co.本年度每股收益将达到8.53美元。

CVS Health Announces Dividend

CVS Health宣布分红

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 1st. Shareholders of record on Friday, October 21st will be paid a dividend of $0.55 per share. The ex-dividend date of this dividend is Thursday, October 20th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.24%. CVS Health's payout ratio is currently 35.77%.

该公司最近还披露了季度股息,将于11月1日(星期二)支付。10月21日(星期五)登记在册的股东将获得每股0.55美元的股息。本次股息除息日期为10月20日(星期四)。这意味着年化股息为2.20美元,股息收益率为2.24%。CVS Health的派息率目前为35.77%。

Insider Buying and Selling at CVS Health

CVS Health的内幕买卖

In other news, EVP Alan Lotvin sold 22,541 shares of the firm's stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $104.00, for a total transaction of $2,344,264.00. Following the sale, the executive vice president now directly owns 109,183 shares in the company, valued at approximately $11,355,032. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, EVP Thomas M. Moriarty sold 138,654 shares of the firm's stock in a transaction dated Tuesday, June 28th. The stock was sold at an average price of $95.00, for a total transaction of $13,172,130.00. Following the sale, the executive vice president now directly owns 626,273 shares in the company, valued at approximately $59,495,935. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Alan Lotvin sold 22,541 shares of the firm's stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $104.00, for a total value of $2,344,264.00. Following the sale, the executive vice president now owns 109,183 shares in the company, valued at $11,355,032. The disclosure for this sale can be found here. Company insiders own 0.69% of the company's stock.

在其他新闻方面,执行副总裁艾伦·洛文在一笔日期为8月4日(星期四)的交易中出售了22,541股公司股票。股票以104.00美元的平均价格出售,总成交金额为2344264.00美元。出售后,执行副总裁总裁现在直接持有该公司109,183股,价值约11,355,032美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可通过此超链接。在其他新闻方面,执行副总裁托马斯·M·莫里亚蒂在6月28日(星期二)的交易中出售了138,654股公司股票。股票以95.00美元的平均价格出售,总成交金额为13172130.00美元。出售后,执行副总裁总裁现在直接持有该公司626,273股,价值约59,495,935美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可通过此超链接。此外,执行副总裁艾伦·洛文在一笔日期为8月4日星期四的交易中出售了22,541股公司股票。这些股票的平均价格为104.00美元,总价值为2,344,264.00美元。出售后,执行副总裁总裁现在拥有该公司109,183股,价值11,355,032美元。关于这次销售的披露可以找到这里。公司内部人士持有该公司0.69%的股份。

Wall Street Analysts Forecast Growth

华尔街分析师预测经济增长

CVS has been the topic of several research analyst reports. Credit Suisse Group increased their price objective on CVS Health from $113.00 to $117.00 and gave the stock an "outperform" rating in a research note on Monday, August 8th. Evercore ISI increased their target price on CVS Health from $120.00 to $125.00 and gave the company an "outperform" rating in a research report on Wednesday, September 7th. Mizuho increased their target price on CVS Health from $115.00 to $120.00 and gave the company a "buy" rating in a research report on Monday, August 15th. UBS Group increased their target price on CVS Health from $118.00 to $127.00 and gave the company a "buy" rating in a research report on Thursday, August 4th. Finally, Loop Capital began coverage on CVS Health in a research report on Thursday, June 16th. They set a "buy" rating and a $120.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $117.59.

CVS一直是几份研究分析师报告的主题。瑞士信贷集团将CVS Health的目标价从113.00美元上调至117.00美元,并在8月8日周一的一份研究报告中给出了该股“跑赢大盘”的评级。9月7日,Evercore ISI在一份研究报告中将CVS Health的目标价从120.00美元上调至125.00美元,并给予该公司“跑赢大盘”的评级。瑞穗将CVS Health的目标价从115.00美元上调至120.00美元,并在15日(周一)的一份研究报告中给予该公司“买入”评级。瑞银集团在8月4日周四的一份研究报告中将CVS Health的目标价从118.00美元上调至127.00美元,并给予该公司“买入”评级。最后,Loop Capital在6月16日星期四的一份研究报告中开始报道CVS Health。他们为该股设定了“买入”评级和120.00美元的目标价。四位股票研究分析师对该股的评级为持有,19位分析师给予了买入评级,一位分析师给予了该公司强烈的买入评级。根据MarketBeat.com的数据,该股目前的普遍评级为“适度买入”,平均目标价为117.59美元。

CVS Health Company Profile

CVS Health公司简介

(Get Rating)

(获取评级)

CVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates.

CVS Health Corporation在美国提供医疗服务。该公司的医疗福利部门提供传统的、自愿的和以消费者为导向的健康保险产品和相关服务。它为雇主团体、个人、大学生、兼职和小时工、健康计划、医疗保健提供者、政府单位、政府支持的计划、劳工团体和外籍人士提供服务。

Read More

阅读更多内容

  • Get a free copy of the StockNews.com research report on CVS Health (CVS)
  • MarketBeat: Week in Review 9/19 – 9/23
  • Why Does Tesla Stock Remain Resilient?
  • Will Crowdstrike Get A Boost From Increased EPS Guidance?
  • Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
  • Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
  • 免费获取StockNews.com关于CVS Health(CVS)的研究报告
  • MarketBeat:回顾一周9/19-9/23
  • 为什么特斯拉的股票保持弹性?
  • CrowdStrike是否会从增加每股收益指引中获得提振?
  • 小盘股的裁员是楼市的晴雨表吗?
  • 好市多盈利后价格疲软是买入的好时机吗?

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVS – Get Rating).

想看看还有哪些对冲基金持有简历吗?访问HoldingsChannel.com获取CVS Health Co.(纽约证券交易所代码:CVS-GET Rating)的最新13F文件和内幕交易信息。

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

接受CVS健康日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对CVS Health和相关公司的最新新闻和分析师评级的每日简要摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发